Conclusions
RESPIRATORY FAILURE
In this study in patients with covid-19 and respiratory failure, anakinra or tocilizumab did not significantly shorten time to clinical improvement compared to usual care. Safety profiles did not differ. However, premature closure of trial and fewer included patients than planned precludes firm conclusions.